Related Experiment Video
Updated: Jun 1, 2026

A High-Fidelity Porcine Model of Orthotopic Heart Transplantation Following Donation after Circulatory Death
Published on: June 6, 2025
Results with expanded donor acceptance criteria in heart transplantation
A Forni1, G B Luciani, B Chiominto
1Division of Cardiovascular Surgery, University of Verona, Verona, Italy. alberto.forni@ospedaleuniverona.it
Insights
Using marginal donors for younger heart transplant recipients and older recipients with optimal donors shows comparable outcomes. Extended donor and recipient criteria are safe for heart transplantation.
Area of Science:
- Cardiology
- Transplantation Medicine
- Immunology
Background:
- Donor and recipient profiles in heart transplantation have evolved.
- Marginal donor utilization in older recipients has yielded satisfactory outcomes.
- Suboptimal donors are increasingly allocated to younger recipients.
Purpose of the Study:
- To retrospectively review the clinical outcomes of heart transplantation using extended donor and recipient criteria.
- To compare outcomes between younger and older recipients receiving either optimal or marginal grafts.
Main Methods:
- Retrospective analysis of 199 heart transplant patients (2000-2010).
- Patients categorized into four groups based on age and donor quality: younger recipients (optimal/marginal donors) and older recipients (marginal/optimal donors).
- Comparison of survival rates, graft failure, rejection episodes, and other complications across groups.
Main Results:
- Overall 10-year survival was 78%.
- No significant differences in 10-year survival or freedom from graft failure, rejection, or other complications were observed among the four groups.
- Older recipients of marginal donors showed a slightly higher, though not statistically significant, rate of permanent pacemaker implantation.
Conclusions:
- Extended donor and recipient criteria in heart transplantation do not appear to compromise clinical outcomes.
- The study supports the safe use of marginal donors in younger recipients and optimal donors in older recipients.
Objective:
Over the past years both donor and recipient profiles have changed in heart transplantation. Satisfactory clinical outcomes of marginal donors in candidates >60 years of age have led us to allocate suboptimal donors to younger recipients as well. Therefore, we retrospectively reviewed our experience.
Methods:
Among 199 patients undergoing heart transplantation from January 2000 to February 2010, there were 83 (41%) aged 61-72 years. The other 116 (59%) ranged in age between 18 and 60 years. According to their clinical conditions as heart transplantation candidates, They were classified into 4 groups: younger recipients (n=116) of either optimal donors (n=72; group 1 [G1]) or marginal donors (n=44; group 2 [G2]) and older recipients (n=83) of either marginal grafts (n=70, group 3 [G3]) or optimal grafts (n=13; group 4 [G4]). The gender distribution, cause of end-stage heart failure, preoperative pulmonary hypertension incidence, pretransplantation clinical status, and mean follow-up were not significantly different among the 4 groups.
Results:
Overall 30-day survival was 90 ± 1% and 10-year rate was 78 ± 9%. Among the groups, 30-day and 10-year actuarial survival rates were, respectively: 94 ± 4% and 87 ± 1% for G1; 86 ± 5% and 84 ± 7% for G2; 88 ± 4% and 71 ± 7% for G3 and were 100% and 82 ± 7% for G4 (P=.7). In comparison among the 4 groups, there was no significant difference regarding freedom from graft failure (P=.3), right ventricular failure (P=.3), acute rejection episodes (P = .2), chronic rejection (P=.2), neoplasia (P=.5), or chronic renal failure (P=.1). Older recipients of marginal donors [G3] had a 4% (n=3) prevalence of permanent pacemaker implant, versus G2: 3% (n=2) among (P=.1).
Conclusion:
Our results suggest that extended donor and recipient criteria do not compromise clinical outcomes after transplantation.
Related Concept Videos
Kidney Transplant I: Introduction
Tissue Transplantation
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...

